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ndometrial cancer (EC) is the most common gynecological cancer, especially in the Western countries. Vaginal bleeding is the major symptom in 90% of the patients. About 75% of the cases are confined to the uterus (FIGO stage I). [1] [2] [3] Bone metastases are encountered in 5-6% of the cases and generally with abdominopelvic recurrences and/or other distant metastases. However, bone metastases as initial symptom for the EC are an extremely rare condition.
2 Although hematologic dissemination is the probable pathway for bone metastasis, the mechanism of initial presentation as bone metastasis in the EC is not clearly understood. 1 Here we report a case of acetabular metastasis as primary presentation of the EC after an informed consent was obtained from the patient.
CASE REPORT
A 67 years old nulliparous Turkish woman admitted to the hospital with right hip pain. Left salpingo-oophorectomy was performed in the past because of benign ovarian cyst. No systemic disease other than hypertension and no significant familial history was noted. Magnetic resonance imaging was realized and a mass in size of 40x66 mm was reported in the posterior of the right acetabulum. Biopsy of the mass was taken and the result was recorded as metastatic adenocarcinoma (Figure 1) . In order to determine the primary focus PET CT was carried out. PET CT revealed that a mass of approximately 78x63 mm causing significant destruction of bone on the Figure  2 ). Therefore, total abdominal hysterectomy+ right salpingo-oophorectomy + left salpingectomy + bilateral pelvic para-aortic lymphadenectomy was administered to the patient. Site-directed radiotherapy was performed to the involved bone region. Gross pathological examination's result was noted as; endometrial adenocarcinoma FIGO grade 2 with involved lymphovascular space and cervical stroma. Two right and one left pelvic lymph nodes were positive. Adjuvant radiotherapy and chemotherapy with zoledronic acid were planned to the patient by a decision of the gynecologic oncology council.
DISCUSSION
As all gynecological cancers, bone metastases from EC are rare. EC is known to spread commonly by direct extension to the adjacent tissues or lymphatic dissemination. Hematogenous metastasis in EC is less frequent and usually seen in the lung and liver. Brain and bone metastases are less common.
4
While, bone involvement is reported to be less than 15% in EC patients with metastatic disease, it is estimated to be about 5-6% in all EC patients and generally in cases with recurrences and/or other distant metastases. 2,4 On the other hand, autopsy based studies suggest an incidence up to 25% for bone metastases originated from EC. 5, 6 However, bone metastases as initial symptom are an extremely rare entity for the EC.
2,6 The incidence of stage IV endometrial cancer is mentioned as 5-10% with less than 10% of 5-years survival rate.
6 Bone metastases are associated with poor prognosis. Nevertheless, prognosis of the isolated metastasis is favorable compared with the multiple ones.
1 Kehoe et al. described 21 EC patients with bone metastasis in their retrospective study. 7 Whereas, 6 patients (29%) presented with a synchronous bone metastasis, 15 patients (71%) had a bone recurrence and the overall survival of these patients was 17 and 32 months, respectively.
7 Myriokefalitaki et al. suggested that EC patients with single bone metastasis should be evaluated as different entity from those with multiple site metastases. 6 They found that the mean survival for patients with single site bone metastasis was 85.7 months which was significantly better than the estimated mean survival of patients with multiple metastases, which was 22.9 months.
6 Single site bone metastasis (acetabulum) was detected in the current study, which was the initial presentation of the case. In the latter study, a review of the literature was made and 29 cases of EC presenting with bone metastases were assessed. Patients' mean age was 61.3 years. Bone 
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pain, swelling, discomfort and/or pathological fracture without post-menopausal bleeding were the initial symptoms of these cases. Our patient was 67 years old and her admission complaint was bone pain.
The rarity of the EC with bone metastases and therefore limited number of studies with small cases in the medical literature had precluded finding out the standard treatment for these patients. 1, 8, 9 Current treatment modalities include primary cytoreductive surgery, radiotherapy, chemotherapy, hormonal therapy or combinations of these treatment options. Bone metastases can be treated by surgical resection especially the isolated ones. Stereotaxic or palliative radiotherapy, radiofrequency with cementoplasty, and systemic chemotherapy or hormonotherapy are the other options. Sites and number of metastatic bones, concomitant extra-osseous metastasis, type of previous treatments and patients' performance status are the important criteria which affect the selection of the management.
1 Our case was treated with a combination of directed radiotherapy for the involved acetabulum, primary surgery, chemotherapy and hormonal therapy.
In conclusion endometrial biopsy should be included in the women patient's screening when investigated for metastatic bone adenocarcinoma.
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